UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April 2025
Commission File Number: 001-38283
InflaRx N.V.
(Translation of registrant’s name into English)
07745 Jena, Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFLARX N.V.
Results of Annual General Meeting of Shareholders
On April 24, 2025, InflaRx N.V. (the “Company”) held its Annual General Meeting of Shareholders (the “Annual General Meeting”). The final results of each of the agenda items submitted to a vote of the shareholders are
as follows:
Agenda Item 3. Adoption of Dutch statutory annual accounts for the financial year ended December 31, 2024.
The Company shareholders approved the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2024.
Agenda Item 5. Instruction to KPMG Accountants N.V. for the external audit of the Company’s statutory annual accounts for the financial year 2025.
The Company shareholders approved the instruction to KPMG Accountants N.V. for the external audit of the Company’s statutory annual accounts for the financial year 2025.
Agenda Item 6. Release from liability for the Company’s directors with respect to the performance of their duties during the financial year ended December 31, 2024.
The Company shareholders approved the release from liability for the Company’s directors with respect to the performance of their duties during the financial year ended December 31, 2024.
Agenda Item 7. Extension of authorization for the Company’s board of directors (the “Board”) to issue shares and grant rights to subscribe for shares.
The Company shareholders approved the extension of authorization for the Company’s board of directors (the “Board”) to issue shares and grant rights to subscribe for shares.
Agenda Item 8. Extension of authorization for the Board to limit and exclude pre-emption rights.
The Company shareholders approved the extension of authorization for the Board to limit and exclude pre-emption rights.
Agenda Item 9. Extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital.
The Company shareholders approved the extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital.
Agenda Item 10. Amendment to the Company’s articles of association.
The Company shareholders approved the amendment to the Company’s articles of association.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
INFLARX N.V.
|
|
|
|
|
|
|
Date: April 24, 2025
|
By:
|
/s/ Niels Riedemann
|
|
|
Name:
|
Niels Riedemann
|
|
|
Title:
|
Chief Executive Officer
|
2
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
|
Deed of Amendment to the Articles of Association, dated April 24, 2025.
|
3